[ 3 / biz / cgl / ck / diy / fa / ic / jp / lit / sci / vr / vt ] [ index / top / reports ] [ become a patron ] [ status ]
2023-11: Warosu is now out of extended maintenance.

/biz/ - Business & Finance

Search:


View post   

>> No.16687452 [View]
File: 1.40 MB, 1048x992, Screen Shot 2019-12-03 at 1.28.36 PM.png [View same] [iqdb] [saucenao] [google]
16687452

>>16687327
Fuggg...
> Only someone being paid to shill would claim Galectin is "nipping at Intercept's heels." Intercept is way ahead in developing a drug to treats non-alcoholic steatohepatitis (NASH), a severe form of fatty liver disease, and its clinical studies to date have been designed using appropriate endpoints.
>Galectin, by comparison, is conducting a phase I "safety" study of its NASH candidate enrolling a tiny number of patients and using endpoints which collect useless biomarker data. It's as if Galectin doesn't really want to find out if their drug is effective against NASH.
>After Emerging Growth's misleading press release was issued Thursday, Galectin followed up with a press release of its own on Friday to announce a conference call for Tuesday morning. The subject of the call: To discuss updated results from its phase I NASH study.
>You think the two press releases might have been coordinated? Galectin pulled the same stunt in March, which helped the company sell stock through an At-The-Market (ATM) equity sales agreement.
>Last November, I explained Galectin's troubled past, including how the company evolved from a bankrupt penny stock.

>2014
still what a shady past
reminds me of another stock that constantly has excuses made for its past

Navigation
View posts[+24][+48][+96]